Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
Nicolas Lanthier, Nathalie M. Delzenne
Cells (2022) Vol. 11, Iss. 17, pp. 2718-2718
Open Access | Times Cited: 19

Showing 19 citing articles:

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 366-366
Open Access | Times Cited: 13
Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
Ludovico Abenavoli, Giuseppe Guido Maria Scarlata, Emidio Scarpellini, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 594-594
Open Access | Times Cited: 28
Prevention of Metabolic Syndrome by Phytochemicals and Vitamin D
Kazuki Santa, Yoshio Kumazawa, Isao Nagaoka
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2627-2627
Open Access | Times Cited: 21
Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome
Alessia Luzzi, Irene Maria Briata, Ilaria Di Napoli, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 6, pp. 1433-1446
Open Access | Times Cited: 6
Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
Xiaoxia Qiu, Sheng‐Li Cheng, Yan‐Hui Liu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 833-842
Open Access | Times Cited: 3
Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors’ Combination
Sergio Quesada‐Vázquez, Caitlin Bone, Shikha Saha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13675-13675
Open Access | Times Cited: 18
Understanding and treating diabetic foot ulcers: Insights into the role of cutaneous microbiota and innovative therapies
Paul Norton, Pavlos Trus, Fengyi Wang, et al.
Skin Health and Disease (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 3
Pathophysiological changes of the liver-muscle axis in end-stage liver disease: what is the right target?
Guillaume Hénin, Nicolas Lanthier, Géraldine Dahlqvist
Acta Gastro Enterologica Belgica (2022) Vol. 85, Iss. 4, pp. 611-624
Open Access | Times Cited: 15
A new strategy to alleviate the obesity induced by endocrine disruptors—A unique lysine metabolic pathway of nanoselenium Siraitia grosvenorii to repair gut microbiota and resist obesity
Yu Wang, Wei Sun, Sen Yan, et al.
Food and Chemical Toxicology (2023) Vol. 175, pp. 113737-113737
Closed Access | Times Cited: 8
Liver Fetuin-A at Initiation of Insulin Resistance
Nicolas Lanthier, Valérie Lebrun, Olivier Molendi‐Coste, et al.
Metabolites (2022) Vol. 12, Iss. 11, pp. 1023-1023
Open Access | Times Cited: 13
Swertia bimaculata moderated liver damage in mice by regulating intestine microbiota
Xiaolei He, Ping Hao, Yun Wang, et al.
Ecotoxicology and Environmental Safety (2023) Vol. 263, pp. 115223-115223
Open Access | Times Cited: 6
The gut microbiota metabolite butyrate mitigates MPTP/MPP+‐induced Parkinson's disease by inhibiting the JAK2/STAT3 signaling pathway
Lili Ji, Tingting Huang, Lun‐Lin Mao, et al.
The Kaohsiung Journal of Medical Sciences (2023) Vol. 39, Iss. 10, pp. 1002-1010
Open Access | Times Cited: 5
Mendelian randomization suggests a causal relationship between gut microbiota and nonalcoholic fatty liver disease in humans
Xiangyi Dai, Kaiping Jiang, Xiaojun Ma, et al.
Medicine (2024) Vol. 103, Iss. 12, pp. e37478-e37478
Open Access | Times Cited: 1
Metabolic steatosis: recent scientific data also support a change in nomenclature
Nicolas Lanthier, Matthew J. Armstrong
Acta Gastro Enterologica Belgica (2023) Vol. 86, Iss. 1, pp. 105-106
Open Access | Times Cited: 2
Are elevated systemic bile acids involved in the pathophysiology of sarcopenia and liver injury following gastric bypass?
S Bourseau, Nadejda Bozadjieva-Kramer, Alexis Goffaux, et al.
Acta Gastro Enterologica Belgica (2023) Vol. 86, Iss. 2, pp. 377-381
Open Access | Times Cited: 2
The Association Between Prevotella copri and Advanced Fibrosis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
Madelaine Leitman, David Zhang, Shrey Pawar, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Review: Microbial Therapeutics for Liver Disease
Cyriac Abby Philips, Philip Augustine
JOURNAL OF GASTROINTESTINAL INFECTIONS (2023) Vol. 13, Iss. 01, pp. 001-016
Open Access | Times Cited: 1
Metabolic-associated fatty liver disease and gut microbiota: pathogenetic relationships and therapeutic targets.
T.D. Zvyagintseva, A. І. Chernobay
Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini (2023) Vol. 2023, Iss. 2, pp. 4-11
Open Access

Abby Cyriac, Philip Augustine
JOURNAL OF GASTROINTESTINAL INFECTIONS (2023) Vol. 13, Iss. 01
Open Access
Page 1

Scroll to top